Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 2INDUSTRY 2NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 1Head & Neck 1

Conditions

Breast Neoplasms 24Hereditary Sensory and Autonomic Neuropathies 6Neoplasms 3Squamous Cell Carcinoma of Head and Neck 2Recurrence 2Ovarian Neoplasms 2Multiple Endocrine Neoplasia Type 1 2Head and Neck Neoplasms 2Advanced Breast Cancer 2Triple Negative Breast Neoplasms 1Stomach Neoplasms Esophageal Neoplasms Metastatic Gastric Cancer Mutated PI3KCA Protein Overexpressed HER2 Protein 1Pre-menopausal Breast Cancer 1Neoplasm Metastasis 1Multiple Myeloma 1Lymphatic Abnormalities 1Lymphangioma, Cystic 1Lymphangioma 1Kidney Neoplasms 1Hyperglycemia 1HER2-positive Metastatic Breast Cancer 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Advanced or Metastatic ER+ Breast Cancer 1Advanced and Selected Solid Tumors 1Advanced Solid Tumors With an Alteration of the PIK3CA Gene 1Advanced Solid Tumor 1Advanced HER2+Breast Cancer 1

Interventions

Dexamethasone 64Cyclophosphamide 35pomalidomide 34Lenalidomide 34Rituximab 31Bortezomib 30venetoclax 28fludarabine 27Gemcitabine 21carfilzomib 20Paclitaxel 19pembrolizumab 17daratumumab 17Cisplatin 16Carboplatin 15Calcium Dobesilate 14Azacitidine 14ibrutinib 12Docetaxel 12Cytarabine 12obinutuzumab 11Nivolumab 11durvalumab 10Injections 10Doxorubicin 10Bevacizumab 10selinexor 9cemiplimab 9blinatumomab 9Cetuximab 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Recurrence × Alpelisib × Clear all
NCT04997902 2026-06-05

Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)

Kura Oncology, Inc.

Phase 1/2 Completed
45 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Recurrence

NCT02144038 2020-12-17

Study of the Safety and Effectiveness of LGH447 and BYL719 in Patients With Relapsed and Refractory Multiple Myeloma

Novartis

Phase 1 Completed
20 enrolled
Plasma cell

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡